Biopharma Adoptive T-Cell Therapy Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Biopharma Adoptive T-Cell Therapy Platforms
1.1 - About Biopharma Adoptive T-Cell Therapy Platforms sector
Companies in Biopharma Adoptive T-Cell Therapy Platforms engineer, develop, and manufacture autologous and allogeneic T-cell therapeutics, including CAR‑T, TCR‑T, and TIL programs. They provide end‑to‑end capabilities spanning discovery, translational research, clinical development, and GMP manufacturing to deliver potent, targeted immunotherapies. The value proposition centers on improving clinical efficacy, expanding pipeline optionality, and de‑risking scale‑up through integrated process, regulatory, and supply chain expertise.
Typical offerings include engineered T-cell products such as CAR‑T, TCR‑T, and TIL therapies built on lentiviral, retroviral, or non‑viral gene delivery with CRISPR/TALEN editing, plus antigen discovery and binder optimization. Companies run closed‑system GMP processing, cell expansion, and QC release assays, alongside cryopreservation and vein‑to‑vein logistics. Many provide process development, comparability and scale‑up, clinical trial operations, and CDMO services, supported by biomarker analytics and bioinformatics to guide patient selection.
Primary customers include oncology biopharma sponsors, large pharmaceutical companies, and hospital cell therapy centers. These providers deliver faster IND filings and study starts, higher manufacturing reliability, and improved clinical response rates through optimized constructs and processes. Outcomes also include reduced cost of goods via allogeneic approaches, streamlined regulatory compliance, and expanded patient access enabled by robust supply chains and centralized manufacturing networks.
2. Buyers in the Biopharma Adoptive T-Cell Therapy Platforms sector
2.1 Top strategic acquirers of Biopharma Adoptive T-Cell Therapy Platforms companies
Janux Therapeutics
- Description: Provider of precision-engineered, tumor-activated immunotherapies that leverage proprietary masking technology to create next-generation T-cell engagers capable of eliciting tumor-specific immune responses while sparing patients’ healthy tissue and overcoming historical toxicity and efficacy limitations.
- Key Products:
- TRACTr Platform: Tumor-activated T-cell engager platform using masking technology to expose binding sites only in tumors, boosting safety and efficacy across multiple solid-tumor indications
- TRACIr Platform (PSMAxCD28): Bispecific immunotherapy delivering CD28 co-stimulation with PSMA targeting to deepen and sustain antitumor responses, designed for combination with JANX007
- JANX007: PSMA-directed TRACTr candidate in Phase 1, engineered to overcome toxicity of existing T-cell engagers and selectively attack prostate tumors
- CD19-ARM Program: Antibody-Receptor Mediated therapy providing rapid, deep and durable B-cell depletion with prolonged memory B-cell reset and no cytokine release syndrome observed preclinically.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Biopharma Adoptive T-Cell Therapy Platforms sector
M&A buyer group 1: Cell Therapy
Precigen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology solutions focused on human gene therapy and gene editing, leveraging proprietary DNA-engineering technologies to control cellular functions and develop treatments such as CAR-T therapies for acute myeloid leukemia.
- Key Products:
- PRGN-3006 CAR-T Therapy: Investigational CAR-T treatment granted orphan drug status targeting acute myeloid leukemia by genetically engineering patient T-cells to attack cancer cells and potentially improve clinical outcomes
- Proprietary DNA Engineering Platform: Suite of complementary technologies that enables precise DNA-based control over cellular functions, supporting creation of diverse gene and cell therapies
- Human Gene Editing Programs: Focused research initiatives applying advanced gene-editing techniques to develop next-generation therapeutics for multiple diseases using Precigen’s engineered cell and gene platforms
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Biopharma Adoptive T-Cell Therapy Platforms sector
3.1 - Buyout funds in the Biopharma Adoptive T-Cell Therapy Platforms sector
2.2 - Strategic buyer groups for Biopharma Adoptive T-Cell Therapy Platforms sector
4 - Top valuation comps for Biopharma Adoptive T-Cell Therapy Platforms companies
4.2 - Public trading comparable groups for Biopharma Adoptive T-Cell Therapy Platforms sector
Valuation benchmark group 1: Cell and Gene Therapy Biopharma Companies
Novartis
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and treatments, focusing on the research, development, manufacturing, and marketing of patented pharmaceuticals in areas such as oncology, immunology, cardiovascular, ophthalmology, and neuroscience to improve and extend lives worldwide.
- Key Products:
- Oncology Treatments: Medications for various types of cancer
- Immunology Drugs: Treatments for autoimmune and inflammatory diseases
- Cardiovascular Medicines: Drugs for heart and vascular conditions
- Neuroscience Therapies: Pharmaceuticals for neurological and psychiatric disorders
- Ophthalmology Solutions: Treatments for eye diseases and conditions